Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 2

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)

NCT06703073 · View on ClinicalTrials.gov ↗

Study Summary

This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress Syndrome (ARDS) utilizing a platform trial design. Participants will be randomized to receive either a placebo or one of the active treatments. This record describes the default procedures and analyses for all cohorts. Each specific cohort may have additional eligibility requirements, safety and efficacy procedures, or endpoints, which will be described in the corresponding intervention-specific records on clinicaltrials.gov listed below in the detailed description.

Interventions

  • DRUG Cohort A: vilobelimab
  • DRUG Cohort A: placebo
  • DRUG Cohort B: paridiprubart
  • DRUG Cohort B: placebo
  • DRUG Cohort C: bevacizumab

Study Locations (20)

California

  • Community Regional Medical Center — Fresno
  • Long Beach Memorial Medical Center — Long Beach
  • University of California Irvine Medical Center — Orange
  • University of California Davis Medical Center - Pulmonary Medicine — Sacramento

Florida

  • Nova Clinical Research — Bradenton
  • North Florida / South Georgia Veterans Health System — Gainesville
  • Sarasota Memorial Hospital — Sarasota

Massachusetts

  • Tufts Medical Center — Boston
  • Lahey Hospital and Medical Center — Burlington

Michigan

  • University of Michigan Hospital — Ann Arbor
  • Henry Ford Health Hospital — Detroit

Alabama

  • University of Alabama Hospital — Birmingham

Colorado

  • Denver Health Hospital and Authority — Denver

District of Columbia

  • MedStar Washington Hospital Center — Washington D.C.

Idaho

  • St. Luke's Boise Medical Center — Boise

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2025-06-10
Est. Completion 2028-09
Phase Phase 2

Sponsor

PPD Development

32 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06703073

The ClinicalTrials.gov registry entry for NCT06703073 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PPD Development, which has 32 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 4 conditions, with Acute Respiratory Distress Syndrome appearing as the primary indexed condition, and to 5 interventions — of which Cohort A: vilobelimab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06703073 reports 20 study locations spanning 13 distinct geographic areas — top geographies include California, Florida, Massachusetts. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06703073 about?

NCT06703073 is a clinical study titled "JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)". This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress Syndrome (ARDS) utilizing a platform trial design. Participants will be random...

What is the current status of trial NCT06703073?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 600 participants. The study started on 2025-06-10. Estimated completion is 2028-09.

What conditions does trial NCT06703073 study?

This clinical trial studies the following conditions: Acute Respiratory Distress Syndrome, ARDS, Acute Respiratory Distress Syndrome (ARDS), ARDS (Acute Respiratory Distress Syndrome). These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06703073?

The interventions under investigation include: Cohort A: vilobelimab (DRUG), Cohort A: placebo (DRUG), Cohort B: paridiprubart (DRUG), Cohort B: placebo (DRUG), Cohort C: bevacizumab (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06703073?

This trial is sponsored by PPD Development, which has 32 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06703073 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial